Abstract
Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Current Pharmaceutical Design
Title: Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Volume: 10 Issue: 28
Author(s): Zhonghua Pei, Gang Liu, Thomas H. Lubben and Bruce G. Szczepankiewicz
Affiliation:
Keywords: protein phosphatase, protein tyrosine phosphatase 1b, ptp1b, ptp1b inhibitors, diabetes, anti-hyperglycemia, insulin resistance, obesity
Abstract: Diabetes is a prevalent disease which effects over 150 million people worldwide and there is a great medical need for new therapeutic agents to treat it. Inhibition of protein tyrosine phosphatase 1B (PTP1B) has emerged as a highly validated, attractive target for treatment of not only diabetes but also obesity. Discovery of small-molecule inhibitors has been pursued extensively in both academia and industry and a number of very potent and selective inhibitors have been identified. With X-ray crystallography, the binding interactions of several classes of inhibitors have been elucidated. This has resulted in significant progress in understanding important interactions between inhibitors and specific residues of PTP1B, which could help the design of future inhibitors. However, since the active site of PTP1B that most of these inhibitors bind to is highly hydrophilic, it remains a challenge to identify inhibitors with both excellent in vitro potency and drug-like physiochemical properties which would lead to good in vivo activities.
Export Options
About this article
Cite this article as:
Pei Zhonghua, Liu Gang, Lubben H. Thomas and Szczepankiewicz G. Bruce, Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382954
DOI https://dx.doi.org/10.2174/1381612043382954 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alkaloids in the Nature: Pharmacological Applications in Clinical Practice of Berberine and Mate Tea
Current Topics in Medicinal Chemistry Cardiovascular Disease: What's All the AGE/RAGE About?
Cardiovascular & Hematological Disorders-Drug Targets Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Myocardial ‘No-Reflow’ Prevention
Current Vascular Pharmacology Aceruloplasminemia
Current Drug Targets Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Hypertensive Treatment and the Metabolic Syndrome
Current Hypertension Reviews Sympathetic Activation in Hypertension and in Hypertension-Related Metabolic Disease
Current Hypertension Reviews Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design Onychomycosis and its Chemotherapy
Current Medicinal Chemistry Vascular Abnormalities in Essential Hypertension
Current Pharmaceutical Design The Correlation Between Urinary 8-Iso-Prostaglandin F2α and Hydrogen Peroxide Toward Renal Function in T2DM Patients Consuming Sulfonylurea and Combination of Metformin-Sulfonylurea
Current Diabetes Reviews Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition
Current HIV Research Cross-linked Mucoadhesive Microspheres based on Anionic Heteropolysaccharide for Nasal Delivery of Felodipine: Optimization and in vitro Evaluation
Drug Delivery Letters Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis and SAR Studies of Urea and Thiourea Derivatives of Gly/Pro Conjugated to Piperazine Analogue as Potential AGE Inhibitors
Protein & Peptide Letters Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design